Related Experiment Video

Updated: Jun 5, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives

Qi He1, Xiaoyan Liu1, Liyan Jiang2

  • 1Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Cancer Biology & Therapy
|December 16, 2024
PubMed

Insights

First-line treatments for KRAS-mutated non-small cell lung cancer (NSCLC) include immunotherapy and chemotherapy. Emerging KRAS inhibitors combined with immunotherapy show future promise for improved outcomes in NSCLC treatment.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • KRAS mutations are prevalent in non-small cell lung cancer (NSCLC), impacting patient prognosis.
  • Targeting KRAS in NSCLC has historically presented significant challenges.
  • Current first-line treatments for KRAS-mutated NSCLC involve immunotherapy, chemotherapy, and chemoimmunotherapy.

Purpose of the Study:

  • To review and summarize existing evidence on first-line therapies for KRAS-mutated NSCLC.
  • To compare treatment outcomes and relevant biomarkers across different first-line regimens.
  • To discuss emerging treatments, including KRAS inhibitors and their potential combination therapies.

Main Methods:

  • Comprehensive literature review of current evidence on first-line therapies for KRAS-mutated NSCLC.
  • Comparative analysis of treatment outcomes and biomarkers for various therapeutic regimens.
  • Discussion of novel agents and combination strategies, particularly KRAS inhibitors with immunotherapy.

Main Results:

  • Immunotherapy, chemotherapy, and chemoimmunotherapy are established first-line options for KRAS-mutated NSCLC.
  • Evidence comparing outcomes and biomarkers for these regimens is summarized.
  • KRAS inhibitors represent a promising area for future therapeutic development, especially in combination with immunotherapy.

Conclusions:

  • This review provides insights into current first-line treatment choices for KRAS-mutated NSCLC.
  • Combination therapies involving KRAS inhibitors and immunotherapy may offer a promising future direction.
  • Further research into novel agents is crucial for advancing the treatment landscape of KRAS-mutated NSCLC.
Keywords:
Kirsten rat sarcoma viral oncogene (KRAS)anti-vascular therapychemotherapyfirst-lineimmune checkpoint inhibitors (ICIs)

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K